AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03950570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer
Study NCT03178617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend standard of care LIP
Study NCT03178617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend HIP
Study NCT03178617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03178617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03178617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03178617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03085485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivacaftor 150 MG
Description: Ivacaftor is a CFTR potentiator
Study NCT03085485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills
Study NCT03152253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text My Quit (TMQ)
Description: Text messages designed to aid smoking cessation
Study NCT03152253 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer Support
Description: A group chat room for peer support
Study NCT03152253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: A group chat room for peer support
Study NCT03152253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Messages
Description: Generic motivational messages not related to smoking cessation
Study NCT04977882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal drainage
Description: 19 Fr abdominal drainage placed intraoperatively in right colic gutter
Study NCT04977882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotico-prophylaxis
Description: Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
Study NCT04977882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical right colectomy with CME and D3 lymphadenectomy (RRC)
Description: the dissection starts over the landmark given by SMV. The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue. Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels. The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH. No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas. At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure. The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia. The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
Study NCT04977882 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic radical right colectomy with CME and D3 lymphadenectomy (RRC)
Description: the dissection starts over the landmark given by SMV. The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue. Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels. The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH. No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas. At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure. The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia. The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
Study NCT04977882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic standard D2 right hemicolectomy (STANDARD)
Description: A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV). The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon. The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
Study NCT04977882 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic standard D2 right hemicolectomy (STANDARD)
Description: A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV). The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon. The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
Study NCT00802074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID
Study NCT00802074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD
Study NCT04108468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate
Study NCT04108468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate
Study NCT00802074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD
Study NCT02449486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Study NCT02449486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT03788993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue-depleted evening light condition
Description: A 20-bedded ward with tunable light emitting diode (LED) lamps. At 18:00h the lighting undergoes a 30-minute transition during which the green and blue LEDs are dimmed to produce blue-depleted amber colored lighting. At 06:50h a new 10-minute transition changes the light color to ordinary indoor lighting. From 07:00h to 18:00h, there is ordinary indoor lighting (3000K colour temperature). The light intensity is dimmed to 20% of the maximum from 23:00h to 6:50h.~Blue-blocking window filters are deployed also in the evening. All TV sets have permanent blue-blocking filters and individuals are provided with blue-blocking screens that can be attached to the front of personal electronic devices. If the patients leave the blue-depleted unit after 18:30 they are offered blue-blocking glasses to wear. The light spectrum in the ward was assessed prior to commencing the RCT and is well-matched to what has been shown in laboratory settings to minimally suppress melatonin.
Study NCT03788993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal light condition
Description: The other half of the unit (20 patient rooms and their corresponding bathrooms and common areas) have ordinary indoor light installed (Glamox, Norway). This has a 3000K color temperature. The light is dimmed to 20% of max in the night, similar to the blue-depleted condition.~The light in the normal light condition and the blue-depleted light condition have similar levels of photopic lux throughout the 24h cycle, but different levels of melanopic lux between 1830h and 0700h.
Study NCT03364465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: change of ventilatory settings
Description: change of tidal volume during one-lung ventilation
Study NCT02322112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose Supplementation
Description: Fifty overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
Study NCT02322112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acacia Gum Supplementation
Description: Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast placebo tablet
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast 10 mg tablet
Description: 1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
Study NCT02322112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4 Supplementation
Description: Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
Study NCT02426905 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: trientine dihydrochloride
Description: A retrospective review of patients' medical records
Study NCT01453270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICOM
Description: Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
Study NCT01453270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
Study NCT00910533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: ceftriaxone 2 g od i.v. for 14 days
Study NCT00183404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
Study NCT02443714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle-free jet injection with insulin lispro
Description: Subjects injected by jet injectors which deliver insulin lispro
Study NCT02443714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional pen injection with insulin lispro
Description: Subjects injected by conventional insulin pens which deliver insulin lispro
Study NCT03738436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy traditional neuromuscular training, NMT
Description: The NMT program includes re-position exercise using Swiss ball roll squat, strengthening and stretching exercises in various positions or combined using Swiss ball, Thera-Band or suspension system (Redcord), balance exercise on wobble board, proper landing strategy practices, and etc.
Study NCT03738436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy modified visual feedback, MVF
Description: traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles
Study NCT02653781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Realistic simulation
Description: The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
Study NCT02653781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control group
Description: The control group will have contents exposed solely from the dialogue-exhibition.
Study NCT02653781 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control group
Description: The control group will have contents exposed solely from the dialogue-exhibition.
Study NCT02653781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation workshop
Description: Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
Study NCT02119351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ViaValve™ Safety IV Catheter
Description: Safety peripheral IV catheter with a blood control feature
Study NCT02119351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProtectIV® Plus Safety IV Catheter
Description: Safety peripheral IV catheter with no blood control feature
Study NCT00843167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract
Description: Given orally
Study NCT00843167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03671837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 15 L/min O2
Study NCT03671837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: 15 L/min air
Study NCT01662310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
Study NCT01662310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
Study NCT03577210 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: augmentation genioplasty
Description: augmentation genioplasty with patient-specific PEEK implant
Study NCT04233866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04233866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT04233866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT04233866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT04233866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT04233866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Given IV
Study NCT02653781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test realistic simulation
Description: Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
Study NCT02653781 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Test realistic simulation
Description: Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
Study NCT04233866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT04233866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04233866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01342770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01342770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Hydrochloride
Description: Given PO
Study NCT01342770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04484428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-285
Description: 88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
Study NCT04484428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: 88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
Study NCT04259268 — intervention group
Intervention type: OTHER
Intervention: Quality of preoperative information register
Description: Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)
Study NCT04259268 — intervention group
Intervention type: OTHER
Intervention: Suitability of information contained in the informed consent
Description: Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
Study NCT03249519 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 50.4 Gy
Study NCT03249519 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: 35-40 Gy
Study NCT03249519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: weekly 40 mg/m\^2 (6cycles)
Study NCT03249519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: 10 times
Study NCT01817413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
Study NCT01817413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularisation
Description: Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone propionate placebo nasal spray
Description: fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
Study NCT01007721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate nasal spray placebo
Description: fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
Study NCT01542489 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study NCT01542489 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study NCT01542489 — intervention group
Intervention type: DRUG
Intervention: human soluble insulin
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study NCT03321851 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: V-sensor device user
Description: Participants use device to detect the 5 vital signs (Blood Pressure, Pulse, Respiration, SpO2, Temperature).
Study NCT01168466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QEEG-based Neurofeedback Training
Description: EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.
Study NCT04258644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1
Description: Combination therapy of 4 drugs, 21 days for one cycle.
Study NCT01309360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
Study NCT01970826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Dental Implants
Description: place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.